Toxic Substance-induced Hippocampal Neurodegeneration in Rodents as Model of Alzheimer’s Dementia

Titis Nurmasitoh1, Dwi Cahyani Ratna Sari2, Rina Susilowati3

1Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 2Department of Physiology, Faculty of Medicine, Universitas Islam Indonesia, Yogyakarta, Indonesia; 3Department of Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

Abstract

BACKGROUND: Alzheimer’s Dementia (AD) cases are increasing with the global elderly population. To study the part of the brain affected by AD, animal models for hippocampal degeneration are still necessary to better understand AD pathogenesis and develop treatment and prevention measures.

AIM: This study was a systematic review of toxic substance-induced animal models of AD using the Morris Water Maze method in determining hippocampal-related memory impairment. Our aim was reviewing the methods of AD induction using toxic substances in laboratory rodents and evaluating the report of the AD biomarkers reported in the models.

METHODS: Data were obtained from articles in the PubMed database, then compiled, categorized, and analyzed. Eighty studies published in the past 5 years were included for analysis.

RESULTS AND DISCUSSION: The most widely used method was intracebroventricular injection of amyloid-β substances. However, some less technically challenging techniques using oral or intraperitoneal administration of other toxic substances also produce successful models. Instead of hippocampal neurodegeneration, many studies detected biomarkers of the AD pathological process while some reported inflammation, oxidative stress, neurotrophic factors, and changes of cholinergic activity. Female animals were underrepresented despite a high incidence of AD in women.

CONCLUSION: Toxic substances may be used to develop AD animal models characterized with appropriate AD pathological markers. Characterization of methods with the most easy-handling techniques and more studies in female animal models should be encouraged.

Introduction

Alzheimer’s dementia (AD) is a problem involving deteriorating cognitive function due to neurodegeneration and a leading cause of disability and dependency in the elderly. It is characterized by memory decline, impaired executive function, and communication problems. The number of cases is currently increasing along with the increasing older population. There were more than 55 million people living with dementia worldwide in 2019, and this is anticipated to triple by 2050 [1]. Although aging is a risk factor for cognitive decline, AD itself is not part of the normal aging process [1], [2]. Until now, no effective dementia therapy is available; hence, prevention efforts are very important to be developed by modifying risk factors to reduce or slow down the pathological process [3]. The study of tissue pathology and molecular biomarkers in the brain of patients with AD is limited due to the invasive examinations required and infrequent autopsies done. Therefore, the use of animal models is still needed to better understand AD pathogenesis, find biomarkers for early diagnosis and develop treatment and prevention modalities.

Rodents are widely used as animal models of neurodegeneration and AD, due to their simplicity in handling and testing compared to larger mammals. Their brain anatomy is analogous to humans. Compared to other brain areas, the hippocampus of animal models of AD shows the most significant changes in the DNA methylation, mRNA (transcriptome), protein (proteome), and metabolite (metabolome) levels. The molecular changes in the hippocampus are correlated with the decrease of cognitive function in animal models, which is in line with the clinical symptoms of AD [4], [5], [6].

At present, various methods are used in inducing AD in animal models, such as using natural aging processes, transgenic animals of AD, various surgery techniques to occlude arteries leading to the brain, and administering a variety of toxic substances. Natural aging processes match the development of AD in humans [6], [7]. However, longer time is needed...
to develop the signs and symptoms. Moreover, the increased mortality rate of aging animals complicates the study design. Mostly involving mice as reviewed in several publications [8], [9], transgenic animals of AD are useful in examining certain pathways in disease pathogenesis. However, the technique requires expensive facilities and high-end expertise that are not suitable for many studies especially in drug development research. Requiring only relatively modest facilities, induction of AD using a variety of toxic substances is a widely used method in drug development studies. However, reviews on toxic substance-induced AD models are limited.

Since cognitive dysfunction is the most prevalent symptom in humans, this parameter should occur in good AD animal models. The Morris Water Maze (MWM) test is the main test for examining cognitive impairment in rodent models of hippocampal neurodegeneration [10], [11]. This systematic review aimed to evaluate the use of toxic substances in rat models of cognitive impairment examined by the MWM test. The technical issue of toxic substance delivery as well as the histological and biochemical parameters presented in the reports will be discussed.

Methods

The search was conducted on the PubMed database on December 9, 2020, at 6:42 Western Indonesian Time by entering the keyword combination (((((dementia) OR (dementia Alzheimer)) OR (Alzheimer)) AND ((degenerati*) OR (neurodegenerati*))))) AND ((hippocamp*))) OR (rat OR (rats))) AND (Morris Water Maze). The inclusion criteria were original reports on hippocampal degeneration and AD using rats as animal models, and MWM as a test for spatial memory examination. The efficacy studies of alternative medicine and drug developments were included when they provided data of untreated models and normal control groups. The exclusion criteria were non-English articles, lack of full text, not using toxic substances as induction technique, have non-significant results in MWM, and studies which used transgenic animal modeling. There was no year limitation in our first search.

The data obtained were compiled in a spreadsheet and categorized based on modeling techniques, characteristics of animal models, tested parameters, and modeling mechanisms in causing hippocampal degeneration and clinical symptoms of AD. The obtained data from the past 5 years (2016–2021) were then analyzed to provide a more detailed description of each model.

Results

The screening of articles

From this search, 255 articles published within 1998 to 2021 were obtained and selected based on the inclusion and exclusion criteria. The filtering process is described in Figure 1. From the screening of titles and abstracts, 61 articles were excluded because they did not meet the criteria, including three articles which were not original articles, three articles written in non-English language, one article which was an incomplete manuscript (only abstract found), and 54 articles which did not use toxic substances. From the remaining 194 full texts, 34 articles were excluded in the rescreening step, that is, ten articles used transgenic animal modeling, two articles aimed to model neurological disease other than AD, three articles using mice, two articles did not test the control group (normal control nor induction control), one article had insignificant results on MWM, and 16 articles used more than one induction. From the 160 articles obtained, 80 articles published in the past 5 years (2016–2021) were included in the study for further analysis.

Figure 1: Screening flowchart for systematic review

Increased reports on this subject were apparent since the number of reports published before 2010 periods were only 21 studies, while 59 studies reported between 2011 and 2015, and 80 studies reported between 2016 and early 2021. The most widely used technique in the past 10 years is the injection of amyloid-β (Aβ) and streptozotocin (STZ). However, over the past 10 years, many other techniques have emerged which have not been used in older studies, that is, the use of trimethyltin (TMT), d-galactose, okadaic acid, monosodium glutamate (MSG), lipopolysaccharide (LPS), high-fat high glucose (HHF) diet, high salt-cholesterol diet (HSCD), virus vectors as carriers of toxic substances, colchicine, cuprizone, letrozole, and scopolamine. All the studies
included in further analysis conducted the MWM test and showed significant results, both in the acquisition test, the probe test, and/or both.

**Experimental animals and modeling methods**

Most of the reports used male Wistar or Sprague-Dawley (SD) rats; each reported by 43 and 30 studies, respectively. Only five studies used female rats (two Wistar rats and three SD rats) (Table 1). Meanwhile, another two studies used male rats but did not mention the strain. The average age of the rats at the necropsy was 5 months. One study induced neonate rats with MSG [12] and the testing and necropsy were done in adulthood.

**Table 1: Number of articles published on 2016–2021 using chemical substance and route of administration**

| Toxic substances | Number of article | Route of Administration |
|------------------|-------------------|-------------------------|
| Amyloid β*       | 35 [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47] | ICV IP Oral Sub-cutaneous |
| Streptozotocin**  | 16 [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63] | 0 0 0 0 |
| Aluminum chloride | 4 [64], [65], [66], [67] | 0 1 3 0 |
| 192IG-saporin     | 4 [68], [69], [70], [71] | 4 0 0 0 |
| D-galactose       | 3 [72], [73], [74] | 0 1 0 2 |
| Scopolamine       | 2 [75], [76] | 0 2 0 0 |
| Okadaic acid      | 2 [77], [78] | 2 0 0 0 |
| Botenic acid      | 2 [79], [80] | 2 0 0 0 |
| Lipopolysaccharide| 2 [81], [82] | 0 2 0 0 |
| Trimethyltin      | 2 [83], [84] | 0 2 0 0 |
| High-fat-high glucose| 2 [85], [86] | 0 0 2 0 |
| D-galactose       | 2 [87], [88] | 0 0 0 1 |
| Monosodium        | 1 [12] | 0 0 0 1 |
| Glutamate         | 1 [89] | 1 0 0 0 |
| Virus vector-APP  | 1 [90] | 1 0 0 0 |
| Colchicine        | 1 [91] | 1 0 0 0 |
| Cuprione          | 1 [92] | 1 0 0 0 |
| High salt diet**  | 1 [93] | 0 0 1 0 |
| Cholesterol diet**| 1 [94] | 0 0 1 0 |
| Letrozole**       | 1 [95] | 0 0 1 0 |
| Total number of articles | 80 | 61 8 8 3 |

*Used female rat: Aβ 2 articles (33,45); STZ 1 article (61); HSCD (90); Letrozol (91)

In the 2016–2021 periods, there was a rapid development in the number and type of induction techniques in research using AD modeling. In the 80 studies reported within the past 5 years, we found 17 modeling techniques Table 1.

The length of interval between induction and MWM test with all methods varied with the different types of induction. The interval was 7 weeks on average, while the fastest was 30 min after induction (of scopolamine injection) [75], and the longest was 32 weeks (HFG diet) [85]. The most widely used administration technique for introducing toxic substances was through the intracerebroventricular (ICV) route (Table 1). Most toxic substance administrations through ICV route used a single dose, except for STZ administration that needed multiple doses. Four studies of ICV administration used multiple doses of Aβ. The ICV route of delivery resulted in the shortest interval time such as reported in ICV colchicine induction (1 week), ICV STZ induction (1–3 weeks), okadaic acid (2 week), 192 Ig-Saporin (2–3 weeks), and ibotenic acid (2–5 weeks).

Although we found one article reported a short 1-week interval, other reports of ICV Aβ induction reported longer intervals of 8 weeks between induction and the MWM tests. By ICV administration, the toxic substance directly accumulates in the central nervous system without any problems in crossing the brain-blood barrier. Therefore, the effect is likely to be faster than systemic administration [92].

Toxic substances administration through intraperitoneal (IP) injection and oral route were also commonly used. LPS, scopolamine, TMT, aluminum chloride, and d-galactose were toxic substances administered through the IP route, while aluminum chloride, cuprizone, and letrozole were toxic substances administered orally. Almost all of the toxic substances given through IP injection and oral routes were done in multiple doses and in a relatively longer time, except TMT that was given at single dose orally 20 days before the MWM test. Among the parenteral routes, subcutaneous administration requires a longer absorption time [93], [94] and a relatively longer interval between induction and behavioral test (12 weeks for MSG, 6–8 weeks for d-galactose, and 6–12 weeks for aluminum). Subcutaneous injection was reported by three studies; two of them used d-galactose; and the other one gave MSG injection to their animal models. Oral induction, such as HFHG [85] and HSCD [90], was seen to have the longest interval, which was about 15–32 weeks.

The most widely used typical marker of AD was the presence of amyloid plaque or Aβ (26 articles), followed by neurofibrillary tangle (NFT) or p-tau (11 articles), glycogen synthase kinase 3 beta (GSK3β) (four articles), beta secretase (βACE) (four articles), amyloid precursor protein (APP) (three articles), and presenilin-1 (PS-1) (one article) Table 2. Examination of typical markers of AD was performed through in situ and biochemical techniques. In situ studies of amyloid plaque markers used mostly immunohistochemical staining techniques and rarely using special staining of Congo Red. Biochemical and qualitative level measurements used enzyme-linked immunosorbent assay, polymerase chain reaction, and Western blotting to determine levels of the typical marker of AD in the level of protein and mRNA.

In addition to examining the typical markers of AD, these studies also examined the markers of the AD pathological process, such as markers of inflammation, oxidative stress, neurotrophic factors, the change of cholinergic activity, and markers of neurodegeneration
(apoptosis, neuronal and hippocampal tissue damage, change of neuronal morphology, decrease of neurogenesis, or neuronal death through both quantitative and qualitative methods). Seventeen studies examined inflammation-related markers, including interleukin-1 (IL1), IL6, IL10, tumor necrosis factor-alpha, nuclear transcription factor-kappa B, peroxisome proliferator-activated receptor γ, XB1, and inducible nitric oxide synthase. Twenty-six studies examined markers of oxidative stress, such as malondialdehyde, reactive oxygen species, and the level of antioxidants such as total antioxidant capacity, total thiols, thiols, superoxide SOD, catalase, glutathione peroxidase, and glutathione. Ten studies examined markers of neurotrophic factors, such as brain-derived neurotrophic factor and vascular endothelial growth factor, and signaling components such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha, cAMP response element-binding protein, sirtuin, protein kinase B (p-AKT), and extracellular signal-regulated kinase. Nineteen studies examined altered cholinergic enzymes, such as activities of choline acetyltransferase and acetylcholinesterase.

Most of the studies (52 studies) examined markers of degenerative neurons such as synaptic damage, pyknotic nuclei, cytoplasmic swelling, neuron shrinkage, vacuolization, lower number of neurons, and decreased volume of the hippocampus. Molecular markers including apoptosis markers: B-cell associated X-protein, B-cell lymphoma protein 2, Caspase-3, terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL), and fluoro jade; neuronal and glial responses: Microtubule associated protein 2, neuronal nuclei, glial fibrillary acidic protein, ionized calcium-binding adaptor molecule 1; and the neurogenesis marker: Bromodeoxyuridine was also frequently reported Tables 2 and 3.

Discussion

The use of chemical substances to induce animal models has been shown to be successful in causing memory impairment [95] as shown with the result of the MWM test. This test examines spatial memory impairment and has been correlated with hippocampal neurodegeneration in rat models [10], [11], [68], Wistar and SD rats are widely used with equal proportions in AD modeling. Both strains of rats are widely available and handled easily with comparable MWM test results.

The pathological process of AD is related to the deposition of amyloid plaque and tau-protein hyperphosphorylation that causes NFT. The formation of Aβ deposition comes from the cleavage of APP by βACE through the amyloidogenic pathway and subsequently produces C-terminal fragment β (CTFβ). The CTFβ fragment is cleaved by secretase-γ which contains the protein PS-1 to produce Aβ peptide. The βACE has been shown to be elevated in AD patients, as APP and PS-1 mutations are also responsible for increased Aβ deposition in patients. The Aβ deposition will cause synaptic disturbance and then lead to excessive tau-protein hyperphosphorylation. Tau-protein hyperphosphorylation leads to pathological intracellular tau protein accumulation to form NFT and subsequently leads to neurodegeneration. Tau phosphorylation is facilitated by tau kinases, including GSK3β and cyclin-dependent kinase 5 (CDK5). Amyloid-deposition also causes the formation of hydrogen peroxide which triggers lipid peroxidation and finally produces an aldehyde compound that is toxic to nerve cells, namely, 4-hydroxynonenal (4-HNE). The formation of 4-HNE also leads to the formation and aggregation of NFT. The Aβ and NFT are neurotoxic and cause oxidative stress and inflammation, hence leading to neuronal death [3], [96], [97], [98].

The typical AD markers such as amyloid plaques and NFT are important parameters to be examined in an AD animal model, yet they were only reported by a limited number of studies. Other typical markers, such as protein PS-1, APP, GSK3β, and βACE, were reported less frequently. Instead, most of the studies examined neurodegeneration markers and markers of processes leading to neurodegeneration such as oxidative stress, inflammation, and neuronal damage. These markers are reported possibly due

Table 2. Number of articles reporting each type of parameter for each toxic-substance-induced animal model

| Toxic substances                      | Typical marker of dementia | Stress oxidative marker | Inflammation marker | Neurotrophic factor | Cholinergic activity | Neuro-degeneration marker |
|---------------------------------------|-----------------------------|------------------------|---------------------|---------------------|----------------------|--------------------------|
| Amyloid β (Aβ)                        | 14                          | 9                      | 3                   | 4                   | 3                    | 5                       |
| Streptozotocin (STZ)                  | 6                           | 5                      | 3                   | 1                   | 5                    | 2                       |
| 1β2Gq-saponin                         | 0                           | 0                      | 1                   | 1                   | 2                    | 4                       |
| Aluminous chloride                    | 3                           | 2                      | 2                   | 1                   | 2                    | 4                       |
| d-galactose                           | 1                           | 2                      | 2                   | 1                   | 2                    | 2                       |
| High fat high glucose (HFHG) diet     | 2                           | 1                      | 2                   | 1                   | 2                    | 1                       |
| Lipo polysaccharide (LPS)             | 0                           | 0                      | 1                   | 0                   | 1                    | 1                       |
| Oxalac acid                           | 2                           | 1                      | 2                   | 0                   | 2                    | 2                       |
| Scopolamine                           | 0                           | 2                      | 0                   | 2                   | 1                    | 0                       |
| Trimethylin (TMT)                     | 0                           | 0                      | 0                   | 0                   | 1                    | 1                       |
| Colchicine                            | 0                           | 1                      | 0                   | 0                   | 1                    | 1                       |
| Cuprione                              | 0                           | 0                      | 0                   | 0                   | 1                    | 1                       |
| Monosodium glutamate (MSG)            | 1                           | 0                      | 1                   | 0                   | 0                    | 0                       |
| High salt & cholesterol diet (HSCD)   | 0                           | 1                      | 1                   | 0                   | 0                    | 0                       |
| Letrozole                              | 1                           | 0                      | 1                   | 0                   | 1                    | 1                       |
| Virus vector-APP                      | 1                           | 0                      | 0                   | 0                   | 0                    | 0                       |
| Total number of articles              | 33                          | 26                     | 17                  | 10                  | 19                   | 52                      |
to the clinical similarity between neurodegenerative processes and AD, especially if the disease includes hippocampal degeneration [99], [100].

Two toxic substances were most frequently used in the studies, that is, Aβ and STZ. ICV administration of Aβ injection is the most widely reported induction technique especially after 2010. The injection of the substance in the form of protein aimed directly into the ventricle of the brain was mostly done by a single dose injection. Only four studies performed the injection in divided doses. These techniques consistently reported amyloid plaque formation in the hippocampus [19]. Increased levels of Aβ and the formation of amyloid plaques stimulate further processes related to AD pathology such as formation of NFT, oxidative stress, inflammation, decrease of neurotrophic factor, changes in cholinergic activity, oxidative stress, neuroinflammation, decreases of neurotrophic factors, changes in cholinergic activity, apoptosis, and other neurodegenerative changes through insulin signaling impairment leading to cognitive and memory deterioration as found in AD [50], [55]. Several studies used the IP route, which was relatively easier than the ICV route. However, this method has not been reported in the past 5 years. Although insulin resistance is correlated with GSK3β activity, tau hyperphosphorylation and amyloid formation [55], previous STZ-induced animal models using the IP route had not reported biomarkers of AD.

Insulin signaling pathway is implicated in AD model induced by HFHG diet through increased CDK5 transcriptional activity that causes hyperphosphorylation of various substrates such as neurofilament, APP and p-tau [85]. Other than STZ, aluminum chloride, MSG, HFHG, and danletrozole were other toxic substances that induce the appearance of typical AD markers through impaired insulin signaling [12], [65], [85], [91]. Normally, insulin binds to the insulin receptor (IR) and further leads to the activation of PI3K/AKT and inactivation of GSK-3β. Insulin resistance is characterized by abnormal GSK-3β activity, responsible for hyperphosphorylation of tau protein, a significant contributor to AD pathogenesis. Other mechanisms in AD pathogenesis may involve reducing the activity of insulin degrading enzymes (IDE) that are responsible for the degradation of insulin as well as Aβ. In a mouse model, IDE gene knockout creates the tendency of excessive APP generated Aβ accumulation in neuronal cells [55].

Biomarkers of AD such as tau hyperphosphorylation and Aβ formation have been
reported in AD models induced by other toxic substances. Okadaic acid induced AD biomarkers through inhibition of serine/threonine phosphatase 1 (PP1) and 2A (PP2) [78]. Ibotenic acid impaired cholinergic neurons in the nucleus basalis of Meynert, a similar sign found in AD. Although the mechanism was not clearly stated, one article reported that APP and amyloid were expressed on ibotenic acid induction [80]. Cuprizone was also one of the toxic substances reported to induce amyloid plaques although the exact mechanism was not elucidated. Cuprizone is able to induce neuronal demyelination and oxidative stress in the brain, causing AD clinical symptoms [67]. One study also reported that β-galactoside induction lead to the presence of Aβ and β-ACE. D-galactose itself has previously been used to induce oxidative stress and brain impairment [74]. TMT administration has been reported to induce memory impairment, typical markers of AD, hippocampal degeneration, neuroinflammation, and decreased neurotrophic factors [68], [100], [101], [102]. In addition, a transcriptomic high-throughput analytical study of TMT revealed differential expression of AD-associated genes such as PS-1 and p-tau [101].

In the HFHG and HSCD induced AD models, the dietary cholesterol cannot pass the blood-brain barrier directly, but it is thought to influence central nervous system homeostasis by increased transport of its circulatory breakdown product, an endogenous selective estrogen receptor namely 27-hydroxycholesterol, into the brain. Most studies investigating the role of cholesterol in increasing the risk of AD has focused on how cholesterol affects APP processing and Aβ protein clearance. The cholesterol-fed animal model of AD shows a multitude of pathological findings similar to those seen in AD patients including Aβ deposits, NFT, and significant increase of markers associated with neurodegeneration in the hippocampus as well as cognitive deficits [103].

Not all studies on AD animal model using toxic substances examined NFT and Aβ deposits but instead used biomarkers of neurodegenerative processes, such as markers of neuronal damage, oxidative stress, and inflammation. A study using HSCD reported that it is associated with neuroinflammation marked by activated NF-kB signaling pathway [90]. Inhibiting NF-kB pathways itself could interrupt neuroinflammation and generation of Aβ [90]. Neuronal death due to oxidative stress and inflammatory processes in the hippocampus results in a lower number of hippocampal pyramidal neurons. While hippocampal neurodegeneration is often reported in toxic substance induced AD models, this hallmark of AD neuropathology is an aspect often lacking in transgenic models [103]. Many studies provided data on the density of pyramidal neurons in the hippocampal area from histological sections [24], [28], [29], [50], [51], [58], [61], [62], [87]. Such data are prone to bias from reference traps [104]. Unbiased stereological techniques of total number of pyramidal neurons in the hippocampus [32], [83] may provide more reliable data on reduced number of neurons upon neuronal death.

The length of interval between induction and MWM test varies with different types of induction. Most studies used mostly young adults of 2–5 months old rats. Although aging is a risk factor for cognitive decline, AD itself is not part of the normal process of aging [2], [3]. Therefore, using younger animals induced by toxic substances may reduce the length of time needed to obtain the desired signs and symptoms of AD [7]. In general, oral administration of toxic substances takes more time to produce desirable signs and symptoms compared to parenteral administration. In the gastrointestinal tract, toxic substances may interact with many digestive enzymes, microbiomes and food components that may neutralize the toxin. Furthermore, the detoxification process in hepatocytes may weaken the effect of the toxin. On the other hand, substance metabolism may produce a derivative substance with more potent toxicity [93].

The interval from the start of induction to the MWM test is the longest in animals undergoing diet modification, such as HSFD and HCSD. Obviously, the longer time and special diet for about 15–32 weeks in producing this model require more resources. Nevertheless, diet modification has an advantage in mimicking the slow pathological changes in human metabolism leading to neurodegeneration [93]. ICV route is the most widely use method and produces a relatively fast model with high reproducibility. However, it is a technically demanding method that also needs special equipment. Scopolamine and TMT are toxic substances typically given intraperitoneally to generate neurodegeneration in AD modeling. Scopolamine is injected repeatedly in multiple dosages, while TMT is injected in a single dose. Scopolamine has a rapid effect, but the duration of its effect is short. Therefore, scopolamine must be given repeatedly, every 30 min before the behavioral examination or termination [75]. TMT can be considered as one of the promising alternative AD induction substances due to several factors, for example, easy administration (IP, single dose) and relatively shorter duration from induction into development of AD characteristics.

Studies using female rats were more limited in number, possibly due to its more complicated nature. Using female rats, researchers must consider the influence of hormones such as estrogen in memory function. Therefore, the study is less appealing for many researchers with limited resources. Studies on sex differences in AD rat models are limited to five studies, that is, two articles using Aβ [33], [45], one study using STZ [61], one study used HSCD [90], and one study used letrozole [91]. Those limited studies reported that female rats are comparable to male rats on MWM, AD markers, and neurodegenerative markers upon toxic...
induction. Nevertheless, further study on female animal models should be encouraged, because the number of women who suffer from AD is actually more than men with AD [33] and sexual differences in animal models of other brain-related diseases have been reported [105]. Differential hormonal secretion and sex chromosome gene expression may induce different pathogenesis, markers, and therapeutic efficacy in women [106].

Conclusion and Future Direction

At least 17 modeling techniques in rats were developed to support AD research and the most widely used technique was injection of Aβ toxic substances. The memory impairment in the rat models was examined with MWM. The presence of both senile plaques and NFT in brain tissue is other characteristics of AD in humans and should be considered to be examined in the brains of AD animal models. The reduced number of neurons in the hippocampus can provide evidence of neuronal degeneration and should be counted with an unbiased method. Additional parameters that were widely examined in studies using AD modeling were the biomarkers of AD pathological processes, such as markers of inflammation, oxidative stress, neurotrophic factors, the change of cholinergic activity, and markers of neurodegeneration. It is still necessary to develop techniques and selection of toxic substances with optimal results and easy-handling techniques. Future study of AD using female rats needs to be encouraged considering the higher number of women who suffer from Alzheimer’s disease compared to men.

References

1. World Health Organization. Global Status Report on the Public Health Response to Dementia. Geneva: World Health Organization; 2021. p. 1-251.
2. Barnes JN. Exercise, cognitive function, and aging. Adv Physiol Educ. 2015;39(2):55-62. PMid:26031719
3. Brini S, Sohrabi HR, Peiffer JJ, Karrasch M, Hämaläinen H, Martins RN, et al. Physical activity in preventing Alzheimer’s disease and cognitive decline: A narrative review. Sport Med. 2018;48(1):29-44. https://doi.org/10.1007/s40279-017-0787-y PMid:28904148
4. Manavalar A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K. Brain site-specific proteome changes in aging-related dementia. Exp Mol Med. 2013;45(e39):1-17. https://doi.org/10.1038/emm.2013.76
5. Durani LW, Hamezah HS, Ibrahim NF, Yanagisawa D, Makpol S, Damanhuri HA, et al. Age-related changes in the metabolic profiles of rat hippocampus, medial prefrontal cortex and striatum. Biochem Biophys Res Commun. 2017;493(3):1356-63. https://doi.org/10.1016/j.bbrc.2017.09.164
6. Hamezah HS, Durani LW, Yanagisawa D, Ibrahim NF, Aizat WM, Bellier JP, et al. Proteome profiling in the hippocampus, medial prefrontal cortex, and striatum of aging rat. Exp Gerontol. 2018;111:53-64. https://doi.org/10.1016/j.exger.2018.07.002 PMid:29981398
7. Salazar C, Valdivia G, Ardiles AO, Ewer J, Palacios AG. Genetic variants associated with neurodegenerative Alzheimer disease in natural models. Biol Res. 2016;49(1):1-9. https://doi.org/10.1186/s40659-016-0072-9
8. Esquerda-Canals G, Montoliu-Gaya L, Güell-Bosch J, Villegas S. Mouse models of Alzheimer’s disease. J Alzheimers Dis. 2017;57(4):1171-83. https://doi.org/10.3233/jad-170045
9. Myers A, McGonigle P. Overview of transgenic mouse models for Alzheimer’s disease. Curr Protoc Neurosci. 2019;89(1):1-21. PMid:31532917
10. Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer’s disease model mice. J Vis Exp. 2011;53:1-6. https://doi.org/10.3791/2920 PMid:21808223
11. Tian H, Ding N, Guo M, Wang S, Wang Z, Liu H, et al. Analysis of learning and memory ability in an Alzheimer’s disease mouse model using the Morris Water Maze. J Vis Exp. 2019;152:1-6. https://doi.org/10.3791/60055 PMid:31736488
12. Jin L, Li YP, Feng Q, Ren L, Wang F, Bo GJ, et al. Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. Neural Regen Res. 2018;13(11):1995-2004. https://doi.org/10.4103/1673-5374.239448 PMid:30233075
13. Huang SW, Wang W, Zhang MY, Liu QB, Luo SY, Peng Y, et al. The effect of ethyl acetate extract from persimmon leaves on Alzheimer’s disease and its underlying mechanism. Phytomedicine. 2016;23(7):694-704. https://doi.org/10.1016/j.phymed.2016.03.009 PMid:27235708
14. Mohammadi M, Guan J, Khodagholi F, Yans A, Khalaj S, Gholami M, et al. Reduction of autopsy markers mediated protective effects of JNK inhibitor and bucladesine on memory deficit induced by Aβ in rats. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(5):501-10. https://doi.org/10.1007/s00210-016-1222-x PMid:26999864
15. Aghassi M, Sharifzadeh M, Sepand MR, Yazdankhah M, Seyednejad SA, Pourrahmad J. A cAMP analog attenuates beta-amyloid (1-42)-induced mitochondrial dysfunction and spatial learning and memory deficits. Brain Res Bull. 2018;140:33-42. https://doi.org/10.1016/j.brainresbull.2018.03.016 PMid:29605485
16. Hooshmandi E, Motamedi F, Moosavi M, Katinger H, Zakeri Z, Zaringhalam J, et al. CEPO-Fc (an EPO derivative) protects hippocampus against Aβ-induced memory deterioration: A behavioral and molecular study in a rat model of Aβ toxicity. Neuroscience. 2018;388:405-17. https://doi.org/10.1016/j.neuroscience.2018.08.001 PMid:30102955
17. Liu Y, Wei M, Yue K, Hu M, Li S, Men L, et al. Study on urine metabolic profile of Aβ(25-35)-induced Alzheimer’s disease using UHPLC-Q-TOF-MS. Neuroscience. 2018;394:30-43. https://doi.org/10.1016/j.neuroscience.2018.10.001 PMid:30316910
18. Song X, Liu B, Cui L, Zhou B, Liu L, Liu W, et al. Estrogen receptors are involved in the neuroprotective effect of silibinin.
19. Azimi M, Gharakhanlou R, Naghdí N, Khodadadi D, Heysieatlabal S. Moderate treadmill exercise ameliorates amyloid-β-induced learning and memory impairment, possibly via increasing AMPK activity and up-regulation of the PGC-1α/FNDC5/BDNF pathway. Peptides. 2018;102:78-88. https://doi.org/10.1016/j.peptides.2017.12.027

20. Chen C, Li B, Cheng G, Yang X, Zhao N, Shi R. Amantdeflavone ameliorates Aβ1-42-induced memory deficits and oxidative stress in cellular and rat model. Neurochem Res. 2018;43(4):857-68. https://doi.org/10.1007/s11064-018-2489-8

21. Aminyavari S, Zahmatkesh M, Farahmandfar M, Khodaghili F, Dargahi L, Zarrindast MR. Protective role of Apelin-13 on amyloid β25-35-induced memory deficit: involvement of autophagy and apoptosis process. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:322-34. https://doi.org/10.1016/j.pnpbp.2018.10.005

22. Garabadu D, Verma J. Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats. Neurochem Int. 2019;128:39-49. https://doi.org/10.1016/j.neuint.2019.04.006

23. Hu W, Feng Z, Xu J, Jiang Z, Feng M. Brain-derived neurotrophic factor modified human umbilical cord mesenchymal stem cells-derived cholinergic-like neurons improve spatial learning and memory ability in Alzheimer’s disease rats. Brain Res. 2019;1710:61-73. https://doi.org/10.1016/j.brainres.2018.12.034

24. Liang S, Wang Z, Yuan J, Zhang J, Zhang J, Qin F, et al. An amyloid-β 1-42 induced Alzheimer’s disease rat model using UHPLC-Q-axactrap qorbitrap mass spectrometry. Molecules. 2019;24:1-24. https://doi.org/10.3390/molecules24142584

25. Shariatpanahi M, Khodagholi F, Ashabi G, Bonakdar Yazdi B, Mehri N, Haddadi R, Ganji M, Shahidi S, Soleimani Asl S, et al. The involvement of protein kinase cβ inhibitor in regulation of apoptosis and autophagy markers in animal model of Alzheimer’s disease. Pharmacol Reports. 2020;72(4):814-26. https://doi.org/10.1007/s43440-019-00017-w

26. Dmytriyeva O, Belmeguenai A, Chonpathompikunlert P, Sroyraya M, Hutamekalin P, Limpawattana M, Klaypradit W. Effects of astaxanthin from shrimp shell on oxidative stress and behavior in animal model of Alzheimer’s disease. Mar Drugs. 2019;17:1-15. https://doi.org/10.3390/md17110628

27. Rezaei Asl Z, Sepehri G, Salami M. Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer’s disease. Behav Brain Res. 2019;376:1-9. https://doi.org/10.1016/j.bbr.2019.112183

28. Sanati M, Khodaghili F, Aminyavari S, Ghasemi F, Gholami M, Kebranizadeh A, et al. Impact of gold nanoparticles on amyloid β1-β4-induced Alzheimer’s disease in a rat animal model: Involvement of STIM proteins. ACS Chem Neurosci. 2019;10(5):2299-309. https://doi.org/10.1021/acschemneuro.8b00622

29. Takisma T, Chonpathompikunlert P, Sroyraya M, Hutamekalin P, Limpawattana M, Klapyradit W. Effects of astaxanthin from shrimp shell on oxidative stress and behavior in animal model of Alzheimer’s disease. Clin Exp Pharmacol Physiol. 2019;46(1):86-93. https://doi.org/10.1111/1440-1681.13020

30. Dara T, Vatanara A, Sharifzadeh M, Khani S, Vakilinezhad MA, Vakhtishet F, et al. Improvement of memory deficits in the rat model of Alzheimer’s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166:1-13. https://doi.org/10.1016/j.nlm.2019.107082

31. Ellob B, Bekker M, Terzioglu Usak S, Dalli T, Kiliç U, Thymoquinone administration ameliorates Alzheimer’s disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta-142 infused rat model. Phytomedicine. 2020;79:1-9. https://doi.org/10.1016/j.phymed.2020.153324

32. Hedayati S, Hedayat CM, Saadat F, Abedinzade M, Nikkar I, Aboutaleib E, et al. Diphtheria toxoid nanoparticles improve learning and memory impairment in animal model of Alzheimer’s disease. Neurochem Res. 2019;43(4):796-805.

33. Heydari S, Dara T, Vatanara A, Sharifzadeh M, Khani S, Vakilinezhad MA, et al. Effects of Vitamin D in an animal model of Alzheimer’s disease: Behavioral assessment with biochemical investigation of hippocampus and serum. Metab Brain Dis. 2020;35(2):263-74. https://doi.org/10.1007/s11011-019-00529-7

34. Mehri N, Haddadi R, Ganji M, Shahidi S, Soleimani Asl S, Taheri Azandarian M, et al. Effects of Vitamin D in an animal model of Alzheimer’s disease: Behavioral assessment with biochemical investigation of hippocampus and serum. Metab Brain Dis. 2020;35(2):263-74. https://doi.org/10.1007/s11011-019-00529-7

35. Soodi M, Saeidnia S, Sharifzadeh M, Hajimehdipoor H, Dashti A, Sepand MR, et al. Satureja bachtiarica ameliorate amyloid-β-induced learning and memory impairment, oxidative stress and cholinergic deficit in animal model of Alzheimer’s disease. Metab Brain Dis. 2016;31(2):395-404. https://doi.org/10.1007/s11011-015-9773-y

36. Shakerin Z, Esfandiari E, Razavi S, Aalai H, Ghadian M, Dashti G. Effects of Cyperus rotundus extract on spatial memory impairment and neuronal differentiation in rat model of Alzheimer’s disease. Adv Biomed Res. 2020;9(17):1-11. https://doi.org/10.4103/abr.abr_173_19

37. Shakerin Z, Esfandiari E, Ghadian M, Razavi S, Aalai H, Dashti G. Therapeutic effects of Cyperus rotundus rhizome extract on memory impairment, neurogenesis and mitochondria in beta-amyloid rat model of Alzheimer’s disease. Metab Brain Dis. 2020;35(3):451-61. https://doi.org/10.1007/s11011-019-00493-2

38. Tu JL, Chen WP, Cheng ZJ, Zhang G, Luo QH, Li M, et al. EGB761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer’s disease. Brain Res. 2020;1736:1-9. https://doi.org/10.1016/j.brainres.2020.146730

39. PMid:32081538

40. PMid:32908011

41. Taksima T, Chonpathompikunlert P, Sroyraya M, Hutamekalin P, Limpawattana M, Klapyradit W. Effects of astaxanthin from shrimp shell on oxidative stress and behavior in animal model of Alzheimer’s disease. Mar Drugs. 2019;17:1-15. https://doi.org/10.3390/md17110628

42. PMid:31690015

43. PMid:30664600

44. PMid:31493483

45. PMid:31982292

46. PMid:32908011

47. PMid:31853828

48. PMid:32048245

49. PMid:31315255

50. PMid:30586546

51. PMid:31315255

52. PMid:28990910

53. PMid:32775310
63. Kaundal M, Deshmukh R, Akhtar M. Protective effect of betulinic acid against intracerebroventricular streptozotocin induced cognitive impairment and neuronal damage in rats: Possible neurotransmitters and neuroinflammatory mechanism. Pharmacol Reports. 2018;70(3):540-8. https://doi.org/10.1016/j.pharep.2017.11.020
PMid:29674241

64. Singh NA, Bhardwaj V, Ravi C, Ramesh N, Mandal AK, Khan ZA. EGCQ nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of Alzheimer’s disease. Front Aging Neurosci. 2018;10:1-13. https://doi.org/10.3389/fagi.2018.00024
PMid:30150930

65. Bazzari FH, Abdallah DM, EI-Abhar HS. Chenodeoxycholic acid ameliorates AlCl3-induced Alzheimer’s disease neurotoxicity and cognitive deterioration via enhanced insulin signaling in rats. Molecules. 2019;24(10):1-17. https://doi.org/10.3390/molecules24101992
PMid:31137621

66. Khalaf NE, El Banna FM, Youssef MY, Mosaad YM, Daba MH, Ashour RH. Clopidogrel combats neuroinflammation and enhances learning behavior and memory in a rat model of Alzheimer’s disease. Pharmacol Biochem Behav. 2020;195:172966. https://doi.org/10.1016/j.pbb.2020.172966
PMid:32474163

67. Ogunlade B, Adelakun SA, Agie JA. Nutritional supplementation of gallic acid ameliorates Alzheimer-type hippocampal neurodegeneration and cognitive impairment induced by aluminum chloride exposure in adult Wistar rats. Drug Chem Toxicol. 2020;2020:1-12. https://doi.org/10.1080/01480545.2020.1754849
PMid:32329360

68. Kang JY, Park SK, Guo TJ, Ha JS, Lee DS, Kim JM, et al. Reversal of trimethyltin-induced learning and memory deficits by 3,5-dicaffeoylquinic acid. Oxid Med Cell Longev. 2018;2018:1-14. https://doi.org/10.1155/2018/6981595
PMid:32061708

69. Gelfo F, Cutuli D, Nobili A, De Bartolo P, D’Amelio M, Petrosini L, et al. Chronic Lithium treatment in a rat model of basal forebrain cholinergic depletion: Effects on memory impairment and neurodegeneration. J Alzheimers Dis. 2017;56(4):1505-18. https://doi.org/10.3233/jad-160892
PMid:28222508

70. Dobryakova YV, Kasianov A, Zaichenko MI, Stepanchev MY, Chensovokoa EA, Kolosov PM, et al. Intracerebroventricular administration of 192lgG-saporin alters expression of microgli-a-associated genes in the dorsal but not ventral hippocampus. Front Mol Neurosci. 2018;10:1-11. https://doi.org/10.3389/fnmol.2017.00429
PMid:29386992

71. Shin J, Kong C, Lee J, Choi BY, Sim J, Koh CS, et al. Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. Alzheimers Res Ther. 2019;11:1-15. https://doi.org/10.1186/s13195-019-0569-x
PMid:31881998

72. Gao J, Zhou R, You X, Luo F, He H, Chang X, et al. Salidroside suppresses inflammation in a d-galactose-induced rat model of Alzheimer’s disease via SIRT1/NF-κB pathway. Metab Brain Dis. 2016;31(4):771-8. https://doi.org/10.1007/s11011-016-9813-2
PMid:26909502

73. Heidari S, Mehr S, Hosseinzadeh H. Memory enhancement and protective effects of crocin against d-galactose aging model in the hippocampus of wistar rats. Iran J Basic Med Sci. 2017;20(11):1250-9.
PMid:29299203

74. Rehman SU, Shah SA, Ali T, Chung JI, Kim MO. Anthocyanins reversed d-galactose-induced oxidative stress and neuroinflammation mediated cognitive impairment in adult rats. Mol Neurobiol. 2017;54(1):255-71. https://doi.org/10.1007/s12035-015-9604-5
PMid:26738855

75. Aksoz E, Gocmez SS, Sahin TD, Aksit D, Aksit H, Utkan T. The protective effect of metformin in scopolamine-induced learning and memory impairment in rats. Pharmacol Reports. 2019;71(5):818-25. https://doi.org/10.1016/j.pharep.2019.04.015
PMid:31382167

76. Nikpour M, Sharafii A, Hamidi M, Andalib S. Effect of colloidal aqueous solution of fullerene (C60) in the presence of a P-glycoprotein inhibitor (verapamil) on spatial memory and hippocampal expression of Sirtuin1, SELADIN1, and AQP1 genes in a rat model of Alzheimer’s disease. ACS Chem Neurosci. 2020;11(17):2549-65. https://doi.org/10.1021/acschemneuro.0c00213

77. Çakır M, Tekin S, Doğanıyigit Z, Erden Y, Soytürk M, Çigremis Y, et al. Cannabinoid Type 2 receptor agonist JWH-133, attenuates okadaic acid induced spatial memory impairment and neurodegeneration in rats. Life Sci. 2019;217:25-33. https://doi.org/10.1016/j.lfs.2018.11.058
PMid:30500552

78. Çakır M, Duzova H, Tekin S, Taslidere E, Kaya GB, Çigremis Y, et al. ACA, an inhibitor phospholipases A2 and transient receptor potential metastatin-2 channels, attenuates okadaic acid induced neurodegeneration in rats. Life Sci. 2017;176(2016):10-20. https://doi.org/10.1016/j.lfs.2017.03.022
PMid:28363841

79. Sadeghi L, Yousefi Babadi V, Tanwir F. Improving effects of Echium amoenum aqueous extract on rat model of Alzheimer’s disease. J Integr Neurosci. 2018;17(3-4):661-9. https://doi.org/10.3233/jin-180093
PMid:30103344

80. Heysieattalab S, Sadeghi L. Effects of delphinidin on pathophysiological signs of nucleus basalis of Meynert lesioned rats as animal model of Alzheimer disease. Neurochem Res. 2020;45(7):1636-46. https://doi.org/10.1007/s11004-020-03027-w
PMid:32297026

81. Goel A, Digvijaya D, Garg A, Kumar A. Effect of Capparis spinosa Linn. Extract on lipopolysaccharide-induced cognitive impairment in rats. Indian J Exp Biol. 2016;54(2):126-32. PMid:26934780

82. Keyomoradzadeh A, Hedayati CM, Abedinzade M, Gazor R, Rostampour M, Taleghani BK. Enriched environment effect on lipopolysaccharide-induced spatial learning, memory impairment and hippocampal inflammatory cytokine levels in male rats. Behav Brain Res. 2020;394:1-7. https://doi.org/10.1016/j.bbr.2020.112814

83. Yuliani S, Mustofa M, Partadiredja G. Turmeric (Curcuma longa L.) extract may prevent the deterioration of spatial memory and the deficit of estimated total number of hippocampal pyramidal cells of trimethyltin-exposed rats. Drug Chem Toxicol. 2016;41(1):62-71. https://doi.org/10.1080/01480584.5.2017.1293067
PMid:28440093

84. Ye M, Han BH, Kim JS, Kim K, Shin I. Neuroprotective effect of bean phosphatidylserine on TMT-induced memory deficits in a rat model. Int J Mol Sci. 2020;21(14):1-13. https://doi.org/10.3390/ijms21144901
PMid:32664537
